Mutant PNPLA3 and wild-type NAFLD showed the same levels of adipocyte inflammatory gene expression, while hepatitis-related pathologies were significantly higher in PNPLA3 mutant patients. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.